Cumberland Pharmaceuticals Inc. (CPIX)Healthcare | Drug Manufacturers - Specialty & Generic | Nashville, United States | NasdaqGS
8.46 USD
-0.19
(-2.197%) ⇩
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 7.99 -0.47 (-0.470%) ⇩ (Aug. 28, 2026, 7:40 p.m. EDT) |
Hot Take ↕ | Aug. 22, 2026, 6:06 a.m. EDT
The investment case here is fundamentally broken despite the recent price recovery. The company is hemorrhaging cash, with revenue contracting by more than half (-56%) and operating margins deeply negative at nearly -19%. The balance sheet is precarious, with debt significantly outweighing cash reserves and a current ratio below 1.0, indicating an inability to meet short-term obligations without further financing. The recent $1.5 billion cash windfall from selling assets provides temporary relief, but it highlights a desperate pivot to survival rather than organic growth. The market has rightly punished this stock with a 28% decline over the last nine years, and the recent surge appears to be a volatile bounce off the lows rather than a reversal of the downtrend. The options market confirms this pessimism, with traders aggressively buying protection against a drop to $3-$5. There is no sustainable business model currently in place; the company is effectively a distressed asset waiting for a buyer or a restructuring, making it a poor candidate for capital preservation or growth. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.132947 |
| AutoARIMA | 0.171219 |
| AutoETS | 0.174912 |
| MSTL | 0.176270 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 30% |
| H-stat | 3.76 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.689 |
| Excess Kurtosis | -0.60 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Ex Dividend Date | 2026-08-02 |
| Last Dividend Date | 2026-08-02 |
| Debt to Equity Ratio | 27.558 |
| Revenue per Share | 2.981 |
| Market Cap | 126,757,088 |
| Forward P/E | 60.43 |
| Beta | 0.11 |
| Profit Margins | -24.64% |
| Website | https://www.cumberlandpharma.com |
As of Aug. 22, 2026, 6:06 a.m. EDT: Speculators are positioning for a significant downside gap, evidenced by massive volume in out-of-the-money puts (1.3k contracts at the $10 strike) compared to negligible call volume. While there is some speculative call flow at distant strikes ($11-$12.50), the overwhelming interest in deep puts suggests a fear of a collapse toward the $3-$5 range rather than a rally.
| Date | Dividend | Yield % |
|---|---|---|
| 2026-08-03 | 1.5 | 20.891365 |
| Attribute | Value |
|---|---|
| 52 Week Change | 1.3441734 |
| Address1 | 1,600 West End Avenue |
| Address2 | Suite 1300 |
| All Time High | 17.75 |
| All Time Low | 1.04 |
| Ask | 8.57 |
| Ask Size | 1 |
| Average Daily Volume10 Day | 83,250 |
| Average Daily Volume3 Month | 92,290 |
| Average Volume | 92,290 |
| Average Volume10Days | 83,250 |
| Beta | 0.11 |
| Bid | 6.38 |
| Bid Size | 2 |
| Book Value | 1.164 |
| City | Nashville |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 8.46 |
| Current Ratio | 0.956 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 9.16 |
| Day Low | 8.45 |
| Debt To Equity | 27.558 |
| Display Name | Cumberland Pharmaceuticals |
| Dividend Date | 1,785,456,000 |
| Earnings Call Timestamp End | 1,785,875,400 |
| Earnings Call Timestamp Start | 1,785,875,400 |
| Earnings Timestamp | 1,785,873,600 |
| Earnings Timestamp End | 1,793,736,000 |
| Earnings Timestamp Start | 1,793,736,000 |
| Ebitda | 1,096,723 |
| Ebitda Margins | 0.02475 |
| Enterprise To Ebitda | 116.052 |
| Enterprise To Revenue | 2.873 |
| Enterprise Value | 127,277,304 |
| Eps Forward | 0.14 |
| Eps Trailing Twelve Months | -0.21 |
| Esg Populated | 0 |
| Ex Dividend Date | 1,785,715,200 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fax | 615 255 0094 |
| Fifty Day Average | 7.0838 |
| Fifty Day Average Change | 1.3762002 |
| Fifty Day Average Change Percent | 0.19427429 |
| Fifty Two Week Change Percent | 134.41734 |
| Fifty Two Week High | 9.28 |
| Fifty Two Week High Change | -0.8199997 |
| Fifty Two Week High Change Percent | -0.08836204 |
| Fifty Two Week Low | 1.85 |
| Fifty Two Week Low Change | 6.61 |
| Fifty Two Week Low Change Percent | 3.572973 |
| Fifty Two Week Range | 1.85 - 9.28 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,249,997,400,000 |
| Float Shares | 8,750,134 |
| Forward Eps | 0.14 |
| Forward P E | 60.42857 |
| Free Cashflow | -191,169 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 88 |
| Fullday Change | -0.19 |
| Fullday Change Percent | -2.19653 |
| Fullday Price | 7.99 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.84950995 |
| Gross Profits | 37,637,108 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.41599998 |
| Held Percent Institutions | 0.16533001 |
| Implied Shares Outstanding | 14,983,107 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Industry Disp | Drug Manufacturers - Specialty & Generic |
| Industry Key | drug-manufacturers-specialty-generic |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Dividend Date | 1,785,715,200 |
| Last Dividend Value | 1.5 |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Sancuso, a transdermal patch for the prevention of nausea and vomiting in patients receiving chemotherapy treatment; Vaprisol, an injection to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia; Vibativ, an injection for the treatment of certain bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections; and Tacilia, an oral capsule for the treatment of H. pylori infection. It also develops ifetroban, a product candidate that has completed Phase II clinical trials for the treatment of cardiomyopathy associated with Duchenne muscular dystrophy, hepatorenal syndrome, portal hypertension, aspirin-exacerbated respiratory disease, systemic sclerosis, and idiopathic pulmonary fibrosis. It serves hospital acute care, gastroenterology, and oncology markets in the United States, China, South Korea, Russia, Mexico, Australia, and Saudi Arabia. The company has a strategic alliance agreement with WinHealth Pharma Group Co. Limited. Cumberland Pharmaceuticals Inc. was incorporated in 1999 and is headquartered in Nashville, Tennessee. |
| Long Name | Cumberland Pharmaceuticals Inc. |
| Market | us_market |
| Market Cap | 126,757,088 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_25240322 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -3,200,959 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 129,603,875 |
| Open | 8.7 |
| Operating Cashflow | 745,969 |
| Operating Margins | -18.98654 |
| Payout Ratio | 0.0 |
| Peg Ratio | 1.67 |
| Phone | 615 255 0068 |
| Post Market Change | -0.47000027 |
| Post Market Change Percent | -5.5555587 |
| Post Market Price | 7.99 |
| Post Market Time | 1,787,960,408 |
| Previous Close | 8.65 |
| Price Hint | 2 |
| Price To Book | 7.268041 |
| Price To Sales Trailing12 Months | 2.8610554 |
| Profit Margins | -0.24644 |
| Quick Ratio | 0.491 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.19 |
| Regular Market Change Percent | -2.19653 |
| Regular Market Day High | 9.16 |
| Regular Market Day Low | 8.45 |
| Regular Market Day Range | 8.45 - 9.16 |
| Regular Market Open | 8.7 |
| Regular Market Previous Close | 8.65 |
| Regular Market Price | 8.46 |
| Regular Market Time | 1,787,947,201 |
| Regular Market Volume | 45,180 |
| Return On Assets | -0.02908 |
| Return On Equity | -0.14387 |
| Revenue Growth | -0.563 |
| Revenue Per Share | 2.981 |
| Sand P52 Week Change | 0.20504117 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 14,983,107 |
| Shares Percent Shares Out | 0.0218 |
| Shares Short | 326,215 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 372,727 |
| Short Name | Cumberland Pharmaceuticals Inc. |
| Short Percent Of Float | 0.0372 |
| Short Ratio | 2.49 |
| Source Interval | 15 |
| State | TN |
| Symbol | CPIX |
| Total Cash | 3,862,402 |
| Total Cash Per Share | 0.258 |
| Total Debt | 4,714,184 |
| Total Revenue | 44,304,312 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.21 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 4.65845 |
| Two Hundred Day Average Change | 3.80155 |
| Two Hundred Day Average Change Percent | 0.81605464 |
| Type Disp | Equity |
| Volume | 45,180 |
| Website | https://www.cumberlandpharma.com |
| Zip | 37,203 |